Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant in the Treatment of Acute Dizziness
NCT07435090Phase 3Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rimegepant in vestibular migraine (VM), recurrent vestibulopathy (RV). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
rimegepant
03
Conditions
vestibular migraine (VM)recurrent vestibulopathy (RV)
Beyond the preview
Go deeper on NCT07435090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07435090.